Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pharming Group N.V (PHAR) Operating Leases: 2018-2024

Historic Operating Leases for Pharming Group N.V (PHAR) over the last 7 years, with Dec 2024 value amounting to $29.9 million.

  • Pharming Group N.V's Operating Leases fell 9.69% to $29.9 million in Q4 2024 from the same period last year, while for Dec 2024 it was $29.9 million, marking a year-over-year decrease of 9.69%. This contributed to the annual value of $29.9 million for FY2024, which is 9.69% down from last year.
  • According to the latest figures from FY2024, Pharming Group N.V's Operating Leases is $29.9 million, which was down 9.69% from $33.1 million recorded in FY2023.
  • In the past 5 years, Pharming Group N.V's Operating Leases registered a high of $33.3 million during FY2022, and its lowest value of $10.2 million during FY2020.
  • In the last 3 years, Pharming Group N.V's Operating Leases had a median value of $33.1 million in 2023 and averaged $32.1 million.
  • In the last 5 years, Pharming Group N.V's Operating Leases skyrocketed by 104.82% in 2021 and then decreased by 9.69% in 2024.
  • Over the past 5 years, Pharming Group N.V's Operating Leases (Yearly) stood at $10.2 million in 2020, then skyrocketed by 104.82% to $20.9 million in 2021, then soared by 59.56% to $33.3 million in 2022, then fell by 0.56% to $33.1 million in 2023, then dropped by 9.69% to $29.9 million in 2024.